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Abstract
Background: Individuals lacking immune recovery during suppressive cART will still represent a clinical issue in the
years to come, given the high proportion of HIV-infected subjects introducing therapy late in the course of disease.
Understanding the mechanisms underlying poor CD4+ T-cell gain is crucial for the correct clinical management of
individuals in this context.
Case presentation: An HIV-infected subject with poor CD4+ T-cell gain in the course of suppressive antiretroviral
therapy was extensively investigated to identify the mechanisms behind inadequate CD4+ reconstitution. In particular, we
studied the phenotype of circulating T-cells, interleukin-7 signaling in peripheral blood and bone marrow, gut function and
microbial translocation markers as well as the composition of the faecal microbiota. Numerous therapeutic interventions
ranging from antiretroviral therapy intensification to immunotherapy and anti-hepatitis C virus treatment were
also employed in order to target the possible causes of poor immune-recovery.
Conclusions: Poor CD4+ T-cell gain on suppressive antiretroviral therapy is multifactorial and thus represents a
clinical challenge. Clinicians should investigate subjects’ immune profile as well as possible causes of chronic antigenic
stimulation for the administration of the most appropriate therapeutic strategies in this setting.
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Background
A low CD4+ T-cell nadir upon combination Antiretroviral
Therapy (cART) introduction in Human Immunedefi-
ciency Virus (HIV) infection is linked to weak CD4+ T-cell
gain [1], exposing subjects to the increased risk of clinical
events [2]. Current guidelines recommend initiation of
treatment early in the course of disease [3, 4], yet data
from numerous study cohorts point to the steadiness of
late diagnosis of HIV and thus cART start in up to 50% of
infected subjects [5]. In line with these observations, it is
conceivable that individuals lacking immune recovery
during suppressive cART will still represent a clinical
issue in the years to come. The understanding of the
mechanisms underlying poor CD4+ T-cell increases in
thus mandatory for the correct management of patients
in this setting.
We report the case of a male subject with persistent
lack of CD4+ T-cell recovery despite long-term cART.
The patient underwent a plethora of targeted therapeutic
interventions following thorough investigation of the
possible underlying causes of poor immune response.
Case presentation
The patient was diagnosed with HIV infection at the age
of 31 in 1994. The main risk factor for HIV infection
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was previous intravenous drug use. Nadir CD4+ T-cell
count was 26/μL. Hepatitis C Virus (HCV) co-infection
was present (genotype 1a) and cytomegalovirus (CMV)
serology was positive. No opportunistic infections were
diagnosed at the time of HIV testing.
cART was initiated with zidovudine, lamivudine and
indinavir/ritonavir which was changed to tenofovir,
lamivudine and lopinavir/ritonavir in 2004. Despite rapid
virological suppression, poor immune recovery was
observed with CD4+ T-cell counts constantly below the
200/μL threshold (Fig. 1a) and impaired CD4+/CD8+
T-cell ratio (i.e. lower than 1 [6]; Fig. 1b).
A low CD4+ T-cell count at the start of cART has been
associated with clinical progression [2, 7] and hampered
immune-reconstitution (reviewed in [8]; [9, 10]); of note, a
low CD4+ T-cell nadir has also been shown to mirror the
complex alterations of peripheral T-cell homeostasis in
HIV infection, ranging from the impairment of lymphocyte
maturation and function to increases in T-cell activation,
death and T-regulatory cell (Treg) activity, which may not
be reverted by treatment [9–20]. In accordance with these
findings also a low CD4/CD8 T-cell ratio has been associ-
ated with skewed immune functions [21, 22] and increased
clinical risk [6].
In 2001 the patient agreed to undergo immune-adjuvant
interleukin-2 (IL-2) therapy, which at the time was being
explored as a possible alternative therapeutic strategy
to cART alone, given its ability to induce CD4+ T-cell
increases and restore CD4+ T-specific responses to
both recall and HIV antigens [23]. Three cycles of IL-2
were administered subcutaneously (1 cycle: 3 × 106 IU
qd, days 1–5 and 8–12) for an overall duration of
3 months. Immune-therapy accounted for transitory
increases in CD4+ T-cell counts that were not, however,
sustained after the interruption of IL-2 cycles (Fig. 1a, b).
Furthermore, the subject was diagnosed with cutaneous
VZV reactivation shortly after immune-therapy. In this
respect, despite the undeniable immunological effects of
adjuvant IL-2 in subjects with poor CD4+ recovery on
cART [24], this strategy was abandoned for the treatment
of HIV infection, given it failed to provide clinical benefit
compared to antiretrovirals alone [25]. Rather, it accounted
for a higher relative risk of progression to AIDS in subjects
with greatest CD4+ expansion [25], finding that was linked
to a sustained increase in Treg cells [26], pointing to a
major pathogenic role of this subset in the clinical out-
come of treated HIV disease.
Inefficient CD4+ T-cell gain during treatment has been
linked to failure in de novo CD4+ T-cell production. In
this respect, impaired thymic [27, 28] and bone marrow
function [29–31] alongside fibrosis of secondary lymphoid
organs [32, 33], may represent possible pathogenic mecha-
nisms underlying poor CD4+ output. A bone marrow
aspirate highlighting hypo-cellularity, matrix fibrosis as
well as severe dysplasia of myeloid, erythroid and platelet
precursors was performed in 2006, while inconclusive
results were obtained from the study of thymic function
through the measurement of T-Cell Receptor Excision
Circles (TREC; not shown). Given the role played by IL-7
in thymopoiesis as well as in the proliferation and survival
of peripheral cells through its interaction with the IL-7
Receptor (IL-7R) on thymocytes, T-cells and bone marrow
macrophages [34], we decided to investigate the IL-7/IL-
7R system in the study patient.
Compared to uninfected controls described elsewhere
[30], the subject displayed lower IL-7 plasma levels
(Fig. 1c), decreased circulating IL-7Rα (CD127)-expressing
CD4+ (Fig. 1d) and IL-7Rα production in Peripheral
Blood Mononuclear Cells (PBMCs) (Fig. 1e). In sharp
contrast with what observed in the periphery, in the pa-
tient’s bone marrow we found increased levels and pro-
duction of IL-7 (Fig. 1f, g) as well as heightened IL-7Rα
expression in Bone Marrow Mononuclear Cells (Fig. 1h).
Further, lower pSTAT5- (Fig. 1i) and Bcl-2-positive CD4+
T-cells (Fig. 1j) were detected following in vitro IL-7
stimulation of the patient’s PBMCs. While promising
results have been produced following the use of adju-
vant therapy with IL-7 in subjects with poor CD4+ T-cell
recovery [35, 36], our findings warrant careful investiga-
tion of the possible reasons behind IL-7 administration
failure in this setting [36], given that dysfunctional IL-7R
signalling may feature discordant subjects [30, 37].
Excessive peripheral CD4+ T-cell destruction may rep-
resent another cause of hampered immune response on
cART and may be due to several features strictly linked
to each other: T-cell activation, ongoing viral replica-
tion/HIV persistence and chronic antigenic stimulation.
In particular, aberrant T-cell activation leading to in-
creased cell death has been constantly associated with
discordant immune responses to therapy [16–18, 28, 38]
and its multifactorial pathogenesis appears to be related
to productive/latent HIV infection, the presence of co-
pathogens (HCV, CMV) and microbial translocation.
Given that stable levels of CD8+ T-cell activation were
observed over the years (Fig. 1k), in 2011 we decided to
expand our knowledge on the subjects’ T-cell homeostasis
by performing a thorough investigation of the CD4+
lymphocyte maturation phenotype. For this purpose,
HIV-uninfected individuals were consecutively enrolled as
a control group (n = 16; median age 31 years, IQR 28–35;
female sex 69%; HCV co-infection 0%) for laboratory
experiments. Our analysis revealed lower frequencies of
naïve (Fig. 1l) and central memory cells (Fig. 1m) as well
as higher CD4+ effector memory (Fig. 1n) and terminally
differentiated lymphocytes (Fig. 1o) compared to controls,
thus pointing to persistent skewing of T-cell homeostasis
despite long-term virological suppression, immunotherapy
and cART intensification (see below).
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Fig. 1 (See legend on next page.)
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Data on the role of ongoing viral replication and
increased reservoirs as a cause of immune activation
and poor immune recovery in course of suppressive
cART have been inconclusive, with proof of a relation-
ship between such features in some studies [28, 39–41]
and not in others [15, 39, 42–44]. Despite full viro-
logical suppression and no history of viral blips (Fig. 1a),
in order to counteract the possible effects of persistent
HIV replication below the limit of detection, in 2007
our patient underwent cART intensification with enfu-
virtide in combination with additional 3 cycles of IL-2
adjuvant therapy, which did not lead to prolonged increases
in CD4+ T-cell numbers (Fig. 1a). cART intensification was
also carried out 4 years later with maraviroc which did not
account for changes in CD4+ recovery (Fig. 1a, b), similarly
to what observed in various studies evaluating the role of
the CCR5-coreceptor inhibitor in subjects with discordant
responses to cART [45–48], and may be due to the
marginal impact of this molecule on T-cell activation in
this setting [45–48]. Overall, intensification strategies with
different classes of antiretrovirals have lead to modest
T-cell gains [45–52] and produced controversial results
regarding T-cell homeostasis [45, 46, 48, 50, 51, 53–57]
and measures of HIV low level-replication/persistence
[49, 51–56, 58–61]. Of note, in more recent years
(2013-ongoing) no replication below the limit of detection
(40 cp/mL) was measured in our subject, with the excep-
tion of two consecutive values, 11 cp/mL and 14 cp/mL,
in 2016.
HIV/CMV co-infection has been described as an
additional cause of discordant immune responses to
cART [62], disturbing T-cell homeostasis [63, 64]. As
mentioned above, the study subject displayed serologic
positivity for previous CMV infection. Although the
precise role of CMV reactivation in this setting is a
matter of controversy [64, 65], valganciclovir administra-
tion was shown to suppress CMV DNA levels and lower
T-cell activation levels [65]. Also HCV co-infection has
been widely described as a factor contributing to impaired
CD4+ T-cell recovery [66] and immune skewing in HIV
disease [67, 68]. Paucity of data exists on the role of HCV
clearance in influencing the course of CD4+ T-cell counts
in subjects on long-term cART [69], however, treatment
of HCV infection may have a beneficial effect on other de-
terminants of discordant immune responses, i.e. T-cell ac-
tivation [70] and liver fibrosis [69].
The patient showed mild progression in terms of
HCV-related liver disease over the years and agreed to
start anti-HCV therapy with dasabuvir, ombitasvir/pari-
taprevir/ritonavir and ribavirin at the end of 2016 (Fib-4:
1.62; liver stiffness measured by transient elastography:
7.1 kPa; fibrosis stage F2).). The subject displayed rapid
HCV RNA abatement (from 22258cp/mL to undetectable
levels at week 8) as well as a sustained virological response
at week 24 (February 2017). CD4+ T-cell numbers showed
a slight rise compared to previous years, yet the subject
still displays persistent CD4 depletion (latest CD4 T-cell
count and CD4/CD8, respectively, 135/μL and 0.17;
Fig. 1a, b). Follow-up is currently ongoing and aside
from information on the kinetics of CD4+ T-cell counts,
it will be interesting to observe the long-term outcome of
direct-acting antiviral agents (DAAs) on peripheral T-cell
homeostasis and other markers of immune function in
the absence of the modulatory effects of pegylated-
interferon-α [71, 72].
Finally, microbial translocation has been extensively
called upon as a cause for T-cell activation and inadequate
CD4+ on cART [73–75], most likely linked to the enduring
structural and anatomical defects of the gastrointestinal
mucosa [76] as well as skewing of the gut microbiota, thus
accounting for impaired local and systemic immunity [76]
and hampered CD4+ reconstitution [77, 78]. Our subject
displayed higher microbial translocation markers compared
to HIV-uninfected controls (lipopolysaccharide: 459 pg/mL
vs 75 pg/mL, IQR 75–79; soluble CD14: 2.2 μg/L vs
1.9 μg/L IQR 1.4–2.4), increased gut permeability parame-
ters (lactulose/mannitole ratio: 0.03) and an outgrowth of
faecal Bacteroides intestinalis/Bacteroides uniformis; fur-
ther, exposure of the patient’s PBMCs to various Toll-Like
Receptor bacterial agonists resulted in a down-regulation
of HLA-DR/CD38 co-expression on CD8+ T-cells. These
findings suggest T-cell hypo-responsiveness to subclinical
endotoxemia in subjects with inadequate CD4+ recovery
[73, 79] and may explain why treatment approaches
targeting microbial translocation have failed to significantly
reduce CD8+ T-cell activation in this setting [80].
(See figure on previous page.)
Fig. 1 CD4+ T-cell kinetics and study of the mechanisms underlying poor immune recovery on cART. Persistent low CD4+ T-cell counts (a) and
CD4+/CD8+ T-cell ratio (b) were registered in the study subject despite the administration of different suppressive cART regimens and immuno-therapy.
Compared to a historical cohort of uninfected controls, the patient also displayed lower peripheral blood IL-7 levels (c), decreased IL-7Rα
(CD127) expression on CD4 + T-cells (d) and IL-7Rα production in Peripheral Blood Mononuclear Cells (PBMCs) (e). In the bone marrow, we
observed elevated IL-7 levels (f), increased production of IL-7 (g) and IL-7Rα (h). Lower pSTAT5- (i) and Bcl-2-expressing CD4+ T-cells (j) upon
IL-7 stimulation were detected in our subject. Stable CD8+ T-cell activation (k) and impairment of CD4+ T-cell maturation (l-o) were also
observed. —— represents the kinetics of CD4+ T-cell counts; −—— represents the kinetics of HIV RNA load (limit of detection: 40 cp/mL).
cART: combination antiretrovrial therapy; 3TC: lamivudine; AZT: zidovudine; IDV/r: indinavir/ritonavir; IL-2: interleukin-2; TDF: tenofovir; LPV/r:
lopinavir/ritonavir; T-20: enfuvirtide; FTC: emtricitabine; MVC: maraviroc; EVG/cobi: elvitegravir/cobicistat; DVG: dolutegravir; DAAs: direct acting
antiretrovirals. IL-7: interleukin-7; IL-7R α: IL-7 receptor α. BBMCs: Bone Marrow Mononuclear Cells. US, unstimulated
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Discussion and conclusions
The present case report highlights the multifactorial origin
of poor CD4+ T-cell gain on suppressive antiretroviral
therapy thus emphasizing the difficulties of its clinical
management. Given that immune failure on effective treat-
ment may still represent a common condition in the future
given delayed cART introduction [5] despite current
recommendations [3, 4], we call for further research on
subjects’ immune profile [20] and possible causes of
chronic antigenic stimulation for the administration of
appropriate therapeutic strategies in this setting.
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